How I diagnose and treat NPM1-mutated AML
- PMID: 33171486
- DOI: 10.1182/blood.2020008211
How I diagnose and treat NPM1-mutated AML
Abstract
Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar multifunctional protein, occur in approximately one-third of adult acute myeloid leukemia (AML). NPM1-mutated AML exhibits unique molecular, pathological, and clinical features, which led to its recognition as distinct entity in the 2017 World Health Organization (WHO) classification of myeloid neoplasms. Although WHO criteria for the diagnosis of NPM1-mutated AML are well established, its distinction from other AML entities may be difficult. Moreover, the percentage of blasts required to diagnose NPM1-mutated AML remains controversial. According to the European LeukemiaNet (ELN), determining the mutational status of NPM1 (together with FLT3) is mandatory for accurate relapse-risk assessment. NPM1 mutations are ideal targets for measurable residual disease (MRD) monitoring, since they are AML specific, frequent, very stable at relapse, and do not drive clonal hematopoiesis of undetermined significance. MRD monitoring by quantitative polymerase chain reaction of NPM1-mutant transcripts, possibly combined with ELN genetic-based risk stratification, can guide therapeutic decisions after remission. Furthermore, immunohistochemistry can be very useful in selected situations, such as diagnosis of NPM1-mutated myeloid sarcoma. Herein, we present 4 illustrative cases of NPM1-mutated AML that address important issues surrounding the biology, diagnosis, and therapy of this common form of leukemia.
© 2021 by The American Society of Hematology.
Similar articles
-
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.Blood Cancer Discov. 2024 Jan 8;5(1):8-20. doi: 10.1158/2643-3230.BCD-23-0144. Blood Cancer Discov. 2024. PMID: 37917833 Free PMC article. Review.
-
Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.Leukemia. 2021 Nov;35(11):3113-3126. doi: 10.1038/s41375-021-01222-4. Epub 2021 Apr 20. Leukemia. 2021. PMID: 33879827 Free PMC article.
-
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492. Int J Mol Sci. 2018. PMID: 30404199 Free PMC article. Review.
-
NPM1-mutated acute myeloid leukemia: from bench to bedside.Blood. 2020 Oct 8;136(15):1707-1721. doi: 10.1182/blood.2019004226. Blood. 2020. PMID: 32609823 Review.
-
Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.Cytometry B Clin Cytom. 2019 Jan;96(1):67-72. doi: 10.1002/cyto.b.21744. Epub 2018 Nov 12. Cytometry B Clin Cytom. 2019. PMID: 30417521
Cited by
-
NPM 1 Mutations in AML-The Landscape in 2023.Cancers (Basel). 2023 Feb 12;15(4):1177. doi: 10.3390/cancers15041177. Cancers (Basel). 2023. PMID: 36831522 Free PMC article. Review.
-
Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia.Clin Interv Aging. 2022 Aug 7;17:1187-1197. doi: 10.2147/CIA.S375000. eCollection 2022. Clin Interv Aging. 2022. PMID: 35967966 Free PMC article.
-
Role of Biomarkers in the Management of Acute Myeloid Leukemia.Int J Mol Sci. 2022 Nov 22;23(23):14543. doi: 10.3390/ijms232314543. Int J Mol Sci. 2022. PMID: 36498870 Free PMC article. Review.
-
A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML).Genes (Basel). 2021 Sep 16;12(9):1426. doi: 10.3390/genes12091426. Genes (Basel). 2021. PMID: 34573408 Free PMC article.
-
Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation.Int J Mol Sci. 2023 Feb 5;24(4):3161. doi: 10.3390/ijms24043161. Int J Mol Sci. 2023. PMID: 36834572 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous